Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies

Kimura, Tomoki; Aikata, Hiroshi; Takahashi, Shojiro; Takahashi, Ippei; Nishibuchi, Ikuno; Doi, Yoshiko; Kenjo, Masahiro; Murakami, Yuji; Honda, Yohji; Kakizawa, Hideaki; Awai, Kazuo; Chayama, Kazuaki; Nagata, Yasushi

doi:10.1111/hepr.12359

Cited by 71 publications

(55 citation statements)

References 20 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identification of lncRNA that are involved in cellular processes contributing to oncogenesis, tumor suppression, or tumorigenesis provides opportunities to develop novel therapeutics for cancer that are based on targeting lncRNA (Kimura, et al, 2015; Sasaki, Ideue, Sano, Mituyama, & Hirose, 2009). These genes differ from protein-coding RNA or miRNA in several ways that need to be considered in analyzing their effects or in exploring their therapeutic potential.…”

Section: Therapeutic Approaches To Targeting Lncrna In Cancersmentioning

confidence: 99%

“…Long RNAs, greater than 200 nucleotides include long intergenic non-coding RNAs (lincRNAs), natural antisense transcripts (NATs), transcribed ultraconserved regions (T-UCRs), long enhancer ncRNAs, non-coding repeat sequences, and pseudogenes. In contrast to some types of small ncRNAs such as microRNAs (miRNAs) and small-interfering RNAs (siRNAs), the mechanism and functions of long ncRNAs (lncRNAs) are very poorly understood (Dingemans, et al, 2014; Kimura et al, 2015; Y. Yang et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma

Parasramka

Maji

Matsuda

et al. 2016

Pharmacology & Therapeutics

174

146

View full text Add to dashboard Cite

The recognition of functional roles for transcribed long non-coding RNA (lncRNA) has provided a new dimension to our understanding of cellular physiology and disease pathogenesis. LncRNAs are a large group of structurally complex RNA genes that can interact with DNA, RNA or protein molecules to modulate gene expression and to exert cellular effects through diverse mechanisms. The emerging knowledge regarding their functional roles and their aberrant expression in disease states emphasizes the potential for lncRNA to serve as targets for therapeutic intervention. In this concise review, we outline the mechanisms of action of lncRNAs, their functional cellular roles, and their involvement in disease. Using liver cancer as an example, we provide an overview of the emerging opportunities and potential approaches to target lncRNA dependent mechanisms for therapeutic purposes.

show abstract

Section: Therapeutic Approaches To Targeting Lncrna In Cancersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma

Parasramka

Maji

Matsuda

et al. 2016

Pharmacology & Therapeutics

174

146

View full text Add to dashboard Cite

show abstract

“…The precise and accurate ablative radiation dose delivery of a relatively large single dose with less than five fractions is generally accepted as SABR [39]. Because of the excellent local control possible with this technique in HCC [48][49][50], this is currently under active investigation and there has been a dramatic increase in the number of registered prospective SABR protocols on the clinicaltrials.gov Factors influencing the strength of the recommendation including the quality of the evidence, presumed patient-important outcomes, and cost Weak (2) Variability in preferences and values, or more uncertainty. Recommendation is made with less certainty, higher cost or resource consumption…”

Section: Techniques Of Ebrtmentioning

confidence: 99%

Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials

Park

Cheng

et al. 2016

Liver Cancer

View full text Add to dashboard Cite

A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based on these results, the committee came to a consensus on the utility and efficacy of RT in the management of HCC according to each disease stage as follows: in early and intermediate stage HCC, if standard treatment is not compatible, RT, including EBRT and SIRT can be considered. In locally advanced stage HCC, combined EBRT with transarterial chemoembolization or hepatic arterial infusion chemotherapy, and SIRT can be considered. In terminal stage HCC, EBRT can be considered for palliation of symptoms and reduction of morbidity caused by the primary tumor or its metastases. Despite the currently reported benefits of RT in HCC, the committee agreed that there is a compelling need for large prospective studies, including randomized phase III trial evidence evaluating the role of RT. Specifically studies evaluating the efficacy and safety of sequential combination of EBRT and SIRT are strongly recommended.

show abstract

“…The dose prescribed for SBRT has been reported as total doses of 30-60 Gy/5-20 Gy per fraction in several studies [15,16,31,36,[40][41][42]76]. With 3D-CRT or IMRT, total doses of 21-60 Gy/1.8-5 Gy per fraction have been reported [18,47,49,51,59,64,65,67,77].…”

Section: Published Dose Fractionation For Each Rt Techniquementioning

confidence: 99%

Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma

Yoon¹,

Seong²

2016

Liver Cancer

View full text Add to dashboard Cite

A multimodal approach to treatment is a basic oncologic principle with proven survival benefits for most cancer types. However, existing guidelines recommend single modalities for treating each stage of hepatocellular carcinoma (HCC). Nonetheless, multimodal approaches can be considered for HCC, depending on the characteristics of the disease in individual cases. Radiotherapy (RT), an effective local modality, is a critical element of most multimodal approaches. Improved RTtechnology and increased understanding of the tolerance of the liver to radiation have contributed to the popularity of RT for treating liver tumors in clinical practice. Consequently, numerous reports have described the effects of RT on liver cancer, despite a lack of stringent evidence for its benefits. RT can be delivered using various technologies and approaches, which may be the source of some confusion. For example, high-dose ablative RT can be curative on its own, or high-dose ablative or conventional RT can complement other treatments such as radiofrequency ablation and transarterial chemoembolization. Combinations of systemic agents and RT can also be applied. This review discusses the optimal selection of RT as part of a multimodal approach for HCC.

show abstract

Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies

Abstract: SBRT was effective and relatively safe for patients with small HCC who were ineligible for resection or ablation therapies.

Cited by 71 publications

References 20 publications

Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma

Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma

Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials

Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma

Contact Info

Product

Resources

About